Valentine Comaills

Dr. Valentine Comaills

orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 July 2014 in Science
Verified
Journal Article
Closed access
PDF file
MYMin Yu
Min Yu
ABAditya Bardia
Aditya Bardia
NANicola Aceto
Nicola Aceto
FBFrancesca Bersani
Francesca Bersani
MMMarissa W. Madden
Marissa W. Madden
DHDaniel A. Haber
Daniel A. Haber
Staying one step ahead of tumors: Cancer treatments require continual adjustment. A drug that works initially will lose its potency as the tumor acquires new mutations that allow it to bypass the drug's lethal effects. To stay ahead of the tumor, oncologists need a noninvasive way to collect tumor cells from patients over the course of their treatment. Analyzing the mutations in these samples may help them choose the right drugs as the tumors change. In a small study of breast cancer patients, Yu et al. show that rare tumor cells circulating in the blood can be captured in viable form and used for this purpose. Science , this issue p. 216

1 February 2017 in Genes & Development
Verified
Journal Article
Open access
PDF file
SYStephanie A. Yazinski
Stephanie A. Yazinski
VCValentine Comaills
Valentine Comaills
RBRémi Buisson
Rémi Buisson
MGMarie-Michelle Genois
Marie-Michelle Genois
HNHai Dang Nguyen
Hai Dang Nguyen
LZLee Zou
Lee Zou
Poly-(ADP-ribose) polymerase (PARP) inhibitors (PARPis) selectively kill BRCA1/2-deficient cells, but their efficacy in BRCA-deficient patients is limited by drug resistance. Here, we used derived cell lines and cells from patients to investigate how to overcome PARPi resistance. We found that the functions of BRCA1 in homologous recombination (HR) and replication fork protection are sequentially bypassed during the acquisition of PARPi resistance. Despite the lack of BRCA1, PARPi-resistant cells regain RAD51 loading to DNA double-stranded breaks (DSBs) and stalled replication forks, enabling two distinct mechanisms of PARPi resistance. Compared with BRCA1-proficient cells, PARPi-resistant BRCA1-deficient cells are increasingly dependent on ATR for survival. ATR inhibitors (ATRis) disrupt BRCA1-independent RAD51 loading to DSBs and stalled forks in PARPi-resistant BRCA1-deficient cells, overcoming both resistance mechanisms. In tumor cells derived from patients, ATRis also overcome the bypass of BRCA1/2 in fork protection. Thus, ATR inhibition is a unique strategy to overcome the PARPi resistance of BRCA-deficient cancers.

6 February 2020 in Science
Verified
Journal Article
Closed access
PDF file
RERichard Y. Ebright
Richard Y. Ebright
SLSooncheol Lee
Sooncheol Lee
BWBen S. Wittner
Ben S. Wittner
KNKira L. Niederhoffer
Kira L. Niederhoffer
BNBenjamin T. Nicholson
Benjamin T. Nicholson
DMDouglas S. Micalizzi
Douglas S. Micalizzi
Metastasis: A matter of translation?: Solid tumors shed a small number of cancer cells into the bloodstream, some of which are believed to contribute to metastasis. The molecular features that confer these circulating tumor cells (CTCs) with metastatic potential are poorly understood. Ebright et al. studied CTCs from breast cancer patients and found that cells with increased expression levels of certain ribosomal proteins and regulators of translation had greater metastatic capacity in a mouse model (see the Perspective by Ma and Jeffrey). Consistent with this finding, patients with higher levels of this subset of CTCs tended to have a poorer prognosis. Science , this issue p. 1468 ; see also p. 1424

31 October 2013 in EMBO Molecular Medicine
Verified
Journal Article
Open access
PDF file
MPMarco Piva
Marco Piva
Giacomo DomeniciGiacomo Domenici
Giacomo Domenici
OIOihana Iriondo
Oihana Iriondo
MRMiriam Rábano
Miriam Rábano
BSBruno Simoes
Bruno Simoes
MVMaria Vivanco
Maria Vivanco
Development of resistance to therapy continues to be a serious clinical problem in breast cancer management. Cancer stem/progenitor cells have been shown to play roles in resistance to chemo‐ and radiotherapy. Here, we examined their role in the development of resistance to the oestrogen receptor antagonist tamoxifen. Tamoxifen‐resistant cells were enriched for stem/progenitors and expressed high levels of the stem cell marker Sox2. Silencing of the SOX2 gene reduced the size of the stem/progenitor cell population and restored sensitivity to tamoxifen. Conversely, ectopic expression of Sox2 reduced tamoxifen sensitivity in vitro and in vivo . Gene expression profiling revealed activation of the Wnt signalling pathway in Sox2‐expressing cells, and inhibition of Wnt signalling sensitized resistant cells to tamoxifen. Examination of patient tumours indicated that Sox2 levels are higher in patients after endocrine therapy failure, and also in the primary tumours of these patients, compared to those of responders. Together, these results suggest that development of tamoxifen resistance is driven by Sox2‐dependent activation of Wnt signalling in cancer stem/progenitor cells.

8 January 2019 in Oncogene
Verified
Journal Article
Open access
PDF file
Giacomo DomeniciGiacomo Domenici
Giacomo Domenici
IAIskander Aurrekoetxea-Rodríguez
Iskander Aurrekoetxea-Rodríguez
BSBruno Simoes
Bruno Simoes
MRMiriam Rábano
Miriam Rábano
SLSo Young Lee
So Young Lee
MVMaria Vivanco
Maria Vivanco
Increased cancer stem cell content during development of resistance to tamoxifen in breast cancer is driven by multiple signals, including Sox2-dependent activation of Wnt signalling. Here, we show that Sox2 increases and estrogen reduces the expression of the transcription factor Sox9. Gain and loss of function assays indicate that Sox9 is implicated in the maintenance of human breast luminal progenitor cells. CRISPR/Cas knockout of Sox9 reduces growth of tamoxifen-resistant breast tumours in vivo. Mechanistically, Sox9 acts downstream of Sox2 to control luminal progenitor cell content and is required for expression of the cancer stem cell marker ALDH1A3 and Wnt signalling activity. Sox9 is elevated in breast cancer patients after endocrine therapy failure. This new regulatory axis highlights the relevance of SOX family transcription factors as potential therapeutic targets in breast cancer.

1 December 2016 in Cell Reports
Verified
Journal Article
Open access
VCValentine Comaills
Valentine Comaills
LKLilian Kabeche
Lilian Kabeche
RMRobert Morris
Robert Morris
RBRémi Buisson
Rémi Buisson
MYMin Yu
Min Yu
SMShyamala Maheswaran
Shyamala Maheswaran
TGF-β secreted by tumor stroma induces epithelial-to-mesenchymal transition (EMT) in cancer cells, a reversible phenotype linked to cancer progression and drug resistance. However, exposure to stromal signals may also lead to heritable changes in cancer cells, which are poorly understood. We show that epithelial cells failing to undergo proliferation arrest during TGF-β-induced EMT sustain mitotic abnormalities due to failed cytokinesis, resulting in aneuploidy. This genomic instability is associated with the suppression of multiple nuclear envelope proteins implicated in mitotic regulation and is phenocopied by modulating the expression of LaminB1. While TGF-β-induced mitotic defects in proliferating cells are reversible upon its withdrawal, the acquired genomic abnormalities persist, leading to increased tumorigenic phenotypes. In metastatic breast cancer patients, increased mesenchymal marker expression within single circulating tumor cells is correlated with genomic instability. These observations identify a mechanism whereby microenvironment-derived signals trigger heritable genetic changes within cancer cells, contributing to tumor evolution.